EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION
Geneva - 8 to 12 October 2007

Assignment of Potency to the 1st International Standard for Protein C, Concentrate, Human
(04/252)

Elaine Gray, William Pickering, and Peter Rigsby

National Institute for Biological Standards and Control, South Mimms, Herts EN6 3QG, UK

© World Health Organization 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors [or editors as appropriate] alone are responsible for the views expressed in this publication.
SUMMARY

Twenty laboratories from 10 countries took part in a collaborative study to assign potency values to 2 proposed World Health Organisation (WHO) international standards: the 2nd International Standard for Protein C, Plasma, Human (02/342) and the 1st International Standard for Protein C, Concentrate, Human (04/252) and also to calibrate the Scientific Standardisation Committee (SSC) secondary plasma standard Lot#3 for Protein C functional activity and antigen. The 2nd International Standard for Protein C, Plasma was established by the ECBS in October 2006 (WHO/BS/06.2045), however one of the participants in the study raised concern over the recommendation of the value assignment on the functional activity of the proposed concentrate standard. The decision to recommend the establishment of this concentrate standard was therefore deferred. Based on further discussion and the consensus opinion of the participants and experts from the SSC of the ISTH, it was decided that this proposed international standard should not be labeled with a functional clotting value as obtained by this collaborative study. A new proposal agreed by consensus was formulated to recommend that the candidate concentrate standard, 04/252 be assigned with potencies relative to the 2nd International Standard for Protein C, Plasma, Human, 02/342 with labeled values of 14.5 IU/ampoule for antigen and 15.0 IU/ampoule for functional chromogenic activity only (no protein C functional activity by clotting assay will be assigned).

INTRODUCTION

In 2006, a collaborative study was carried out to value assign a replacement international standard for protein C, plasma and a new international standard for protein C, concentrate. The candidate plasma preparation, 02/342 was subsequently established by the Expert Committee on Biological Standardisation (ECBS) of the World Health Organisation (WHO) in October 2006 as the 2nd International Standard (IS) for Protein C, Plasma, Human. It was value assigned against the 1st International Standard for Protein C, Plasma, Human (86/622) and the labelled values are 0.85 and 0.84 IU/ampoule for function and antigen respectively.

For the proposed concentrate standard, 04/252, all participants and the SSC subcommittee approved the proposed assigned antigenic value of 14.3 IU/ampoule against the 1st IS plasma. However, based on their in-house experience, one participant did not agree with assigning the candidate with an overall functional potency ie combining the values obtained for chromogenic and clotting assays. As this has implications for the comparability of the proposed candidate with clinical products, further consideration and study was required to clarify this issue and so the recommendation to establish the 1st IS for Protein C, Concentrate was deferred until more discussion and/or data were available.

NIBSC and the participant who raised this concern have now carried out a joint study involving assays of a number of their production batches by chromogenic and clotting methods and have found that there is a distinct discrepancy between the potencies obtained by chromogenic and clotting assays. Taking into consideration that 02/342 has been established as the 2nd IS, we have now come up with new proposals for 04/252, the proposed concentrate standard.
SUMMARY OF RESULTS

Details of the collaborative study are described in the participants report (sent to all participants in May 2006) and in the WHO ECBS report WHO/BS/06.2045\(^1\) (available upon request from David Wood, woodd@who.int). The following gives a summary of data from this collaborative study that relates to the calibration of the proposed concentrate standard against the 1st IS for Protein C, Plasma, Human, 86/622 (sample A in the collaborative study) and the 2nd IS for Protein C, Plasma, Human, 02/342 (sample B in the collaborative study).

Tables 1 – 3 show the individual laboratory geometric mean potencies and the % geometric coefficient of variation (GCV) of the proposed concentrate standard as estimated by functional chromogenic assay, functional clotting assay and antigen measurement relative to the 1st and 2nd IS for Protein C, Plasma. Table 4 shows a comparison of potencies of the proposed concentrate standard against the 1st and the 2nd IS for Protein C, Plasma. Statistical analysis shows that there is no significant difference between the potencies obtained against the 1st or the 2nd IS.

STABILITY

Stability of the Proposed WHO 1st IS for Protein C, concentrate has been assessed in an accelerated degradation study which involves the potency estimation of ampoules stored at elevated temperatures relative to ampoules stored at -150 °C. The study was carried out in one laboratory (NIBSC), using a chromogenic assay with Protac® activation. To date, 16 months storage data is available. The observed relative potencies (from 2 independent assays) was analysed using the Arrhenius equation in order to provide a prediction of loss per year for ampoules stored at various temperatures. Because of insufficient loss of activities at the various temperatures and time points, the Arrhenius equation was unable to give a prediction of loss of activity per year. The accelerated degradation study and real time monitoring will continue for the lifetime of the standard.

DISCUSSION

The inter-laboratory variability for the proposed concentrate standard was higher than for other plasma samples (details shown in WHO/BS/06.2045). Despite pre-dilution with protein C deficient plasma, approximately 50% of the assays for the proposed concentrate standard against the 1st IS plasma were still non-parallel and therefore invalid. These assays were not included in the assignment of potencies. This supports the need to assay like against like and the use of a concentrate standard for concentrates may yield more valid assays.

It is clear from further discussion that assigning a functional potency by combining the chromogenic and clotting values will cause a problem with the therapeutic products as these have been calibrated against the plasma IS. In addition, the chromogenic value was found to be significantly different to the clotting value albeit that only 3 laboratories produced valid clotting results that were included in the value assignment. The options from this scenario are value assign only with chromogenic potency or separate chromogenic and clotting potencies.

In addition, as the 2nd IS has been established and there is no significant difference between the potencies against the 1st and the 2nd plasma IS, the value assigned should be against the 2nd IS rather than the 1st IS.
We therefore suggested that the candidate concentrate standard, 04/252 be assigned with potencies relative to the 2nd International Standard for Protein C, Plasma, 02/342 and presented the following options to the participants of the study:

a. Label with chromogenic and antigenic value:

   Functional Chromogenic Activity: 15.0 IU/ampoule;
   Antigen: 14.5 IU/ampoule

b. Label with functional chromogenic and clotting potency and antigen value

   Functional Chromogenic Activity: 15.0 IU/ampoule;
   Functional Clotting Activity: 11.7 IU/ampoule
   Antigen: 14.5 IU/ampoule

PARTICIPANTS RESPONSE

All participants agreed with the proposed assigned value for antigen and the proposed assigned value for functional chromogenic activity. Five out of the 20 participants also agreed with labelling with functional clotting potency

SSC EXPERTS RESPONSES

All nine experts who responded to the review request agreed with the assigned values for antigen and functional chromogenic activity. Three experts made the following comments:

Comment 1

- I recall when the IU for FVIII was realigned arising out of the calibration of the 4th WHO IS and this did cause problems as manufacturers of commercial reference plasmas changed over. For this reason I strongly support the decision to maintain the IU and ignore the fact that the values against pooled normal plasma were slightly different
- I agree with the proposal to accept 04/252 as the 1st IS for PC concentrates
- I agree with the Antigen potency of 15.0 IU/ampoule ( against the 2nd IS for PC in plasma)
- I agree with the proposal to assign a chromogenic potency of 15.0 IU/ampoule.
- The clotting assays are more of a problem. There are several different clotting protein C assays and there is the possibility that different tests could give different results. The 3 centres who performed clotting assays on the proposed concentrate sample all used different methods (Stago, IL, in house) The 95% confidence intervals for the clotting PC results (10.4 -13.1 IU/ampoule) do not overlap with the chromogenic (14.1- 15.9) so this seems to be a real difference. On the other hand they are wider and since there are only 3 results , each by different methods (with means of 11.5, 13.4 and 10.8) I think it is safer not to assign a clotting value. Is it possible to include the data relating to clotting assays for information only in the supporting documentation when issuing the standard, which would prevent a manufacturer making the false assumption that the chromogenic functional assigned potency was suitable for use with clotting assays.
Comment 2

The chromogenic assays measured significantly higher protein C activity than the clotting assays. Without knowing definitively why the results of these two types of protein C activity assays differ significantly, it would be best to report only the chromogenic assay potency which is similar to the antigenic potency.

Comment 3

I would favor adopting as standard, with option 1 - just chromogenic and antigenic values. You may want to reference the issue with the clotting assay in the package insert.

PROPOSAL AND RECOMMENDATION

Taking into account the responses of the participants and the SSC experts, it is proposed to recommend that the candidate concentrate standard, 04/252 be assigned with potencies relative to the 2nd International Standard for Protein C, Plasma, Human, 02/342 with the following values for:

Functional Chromogenic Activity: 15.0 IU/ampoule;  
Antigen: 14.5 IU/ampoule

PRODUCT SUMMARY FOR 04/252

The candidate 1st IS for Protein C, Concentrate, Human was prepared from a batch of plasma derived protein C clinical concentrate. The bulk material was diluted to approximately 15 U/mL with 50mM Tris, 150 mM NaCl, 5mg/mL human albumin, 2mg/mL trehalose, pH 7.3. The final ampouled material was produced as described by Campbell, 1974 and the finished product summary is as follows:

<table>
<thead>
<tr>
<th>Code number</th>
<th>04/252</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation</td>
<td>Sealed, glass 5 ml DIN ampoules</td>
</tr>
<tr>
<td>Number of ampoules available</td>
<td>3000</td>
</tr>
<tr>
<td>Date filled</td>
<td>19 May 2005</td>
</tr>
<tr>
<td>Precision of fill – CV of fill mass (% , n = 44)</td>
<td>0.32</td>
</tr>
<tr>
<td>Residual moisture after lyophilisation and secondary desiccation (% , n = 6)</td>
<td>0.09</td>
</tr>
<tr>
<td>Mean dry weight (g, n=6)</td>
<td>0.03</td>
</tr>
<tr>
<td>Storage conditions</td>
<td>-20 °C</td>
</tr>
<tr>
<td>Address of processing facility</td>
<td>NIBSC, Potters Bar, EN6 3QG, UK</td>
</tr>
<tr>
<td>Address of present custodian</td>
<td>NIBSC, Potters Bar, EN6 3QG, UK</td>
</tr>
</tbody>
</table>

A proposed Instruction For Use and Material Safety Data is shown in appendix 2.
ACKNOWLEDGEMENT

We would like to acknowledge the donation of the protein C concentrate by Baxter AG (Vienna, Austria), the participants of the study (Appendix 1), the SSC experts (Trevor Barrowcliffe, Eric Preston, Herb Whinna, Francesco Bernardi, Fred Ofosu, John Brandt, Mark Weinstein, Craig Jackson and Steve Kitchen) for reviewing the study report, the support of the Plasma Coagulation Inhibitors Subcommittee of the SSC of the ISTH, Paul Matejtschuk (TDI, NIBSC) for formulation and trial fills of the candidates and the staff of the CBRM, NIBSC for filling the candidates.

REFERENCES

1. WHO/BS/06.2045
Table 1: Potencies of sample C, the proposed 1st IS for Protein C, Concentrate in chromogenic assays

<table>
<thead>
<tr>
<th>Lab</th>
<th>Potency relative to A (0.82 IU/amp)</th>
<th>Potency relative to B (0.85 IU/amp)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Geometric Mean</td>
<td>GCV</td>
</tr>
<tr>
<td>5</td>
<td>13.38</td>
<td>5.9</td>
</tr>
<tr>
<td>6</td>
<td>13.97</td>
<td>5.9</td>
</tr>
<tr>
<td>7</td>
<td>14.18</td>
<td>2.0</td>
</tr>
<tr>
<td>9</td>
<td>14.49</td>
<td>.</td>
</tr>
<tr>
<td>10</td>
<td>14.03</td>
<td>8.0</td>
</tr>
<tr>
<td>11</td>
<td>15.80</td>
<td>0.8</td>
</tr>
<tr>
<td>17</td>
<td>17.24</td>
<td>.</td>
</tr>
<tr>
<td>20</td>
<td>15.97</td>
<td>2.0</td>
</tr>
<tr>
<td>21</td>
<td>14.99</td>
<td>3.1</td>
</tr>
<tr>
<td>22</td>
<td>14.30</td>
<td>0.4</td>
</tr>
<tr>
<td>23</td>
<td>14.61</td>
<td>4.2</td>
</tr>
</tbody>
</table>

Table 2: Potencies of sample C, the proposed 1st IS for Protein C, Concentrate in clotting assays

<table>
<thead>
<tr>
<th>Lab</th>
<th>Potency relative to A (0.82 IU/amp)</th>
<th>Potency relative to B (0.85 IU/amp)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Geometric Mean</td>
<td>GCV</td>
</tr>
<tr>
<td>5</td>
<td>11.50</td>
<td>4.2</td>
</tr>
<tr>
<td>6</td>
<td>13.37</td>
<td>4.2</td>
</tr>
<tr>
<td>9</td>
<td>10.83</td>
<td>.</td>
</tr>
</tbody>
</table>

Table 3: Potencies of sample C, the proposed 1st IS for Protein C, Concentrate in antigen assays

<table>
<thead>
<tr>
<th>Lab</th>
<th>Potency relative to A (0.82 IU/amp)</th>
<th>Potency relative to B (0.84 IU/amp)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Geometric Mean</td>
<td>GCV</td>
</tr>
<tr>
<td>5</td>
<td>13.48</td>
<td>.</td>
</tr>
<tr>
<td>6</td>
<td>11.64</td>
<td>19.6</td>
</tr>
<tr>
<td>7</td>
<td>14.81</td>
<td>.</td>
</tr>
<tr>
<td>10</td>
<td>14.15</td>
<td>12.6</td>
</tr>
<tr>
<td>17</td>
<td>15.69</td>
<td>.</td>
</tr>
<tr>
<td>23</td>
<td>16.54</td>
<td>3.7</td>
</tr>
</tbody>
</table>
Table 4: Potencies of sample C, the proposed 1st IS for Protein C, Concentrate

<table>
<thead>
<tr>
<th>Standard</th>
<th>Geometric mean potency (IU/amp), 95% confidence interval and between-lab GCV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chromogenic:</td>
</tr>
<tr>
<td></td>
<td>Clotting:</td>
</tr>
<tr>
<td></td>
<td>Combined:</td>
</tr>
<tr>
<td></td>
<td>Antigen:</td>
</tr>
<tr>
<td>1st IS plasma</td>
<td>0.82 IU/amp</td>
</tr>
<tr>
<td>14.77</td>
<td>(14.07–15.52)</td>
</tr>
<tr>
<td>7.6%</td>
<td>(9.05–15.52)</td>
</tr>
<tr>
<td>n=11</td>
<td>11.5%</td>
</tr>
<tr>
<td>14.10*</td>
<td>(13.14–15.12)</td>
</tr>
<tr>
<td>14.29</td>
<td>(12.55 – 16.28)</td>
</tr>
<tr>
<td></td>
<td>11.86</td>
</tr>
<tr>
<td>11.5%</td>
<td>12.9%</td>
</tr>
<tr>
<td>n=3</td>
<td>n=14</td>
</tr>
<tr>
<td>14.45</td>
<td>14.1%</td>
</tr>
<tr>
<td>n=6</td>
<td>n=6</td>
</tr>
<tr>
<td>2nd IS plasma</td>
<td>0.85 IU/amp</td>
</tr>
<tr>
<td>14.98</td>
<td>(14.14 – 15.86)</td>
</tr>
<tr>
<td>8.9%</td>
<td>(10.37 – 13.12)</td>
</tr>
<tr>
<td>n=11</td>
<td>4.9%</td>
</tr>
<tr>
<td>14.20*</td>
<td>(13.16 – 15.32)</td>
</tr>
<tr>
<td>14.45</td>
<td>(12.68 – 16.46)</td>
</tr>
<tr>
<td></td>
<td>11.67</td>
</tr>
<tr>
<td>13.2%</td>
<td>n=14</td>
</tr>
<tr>
<td></td>
<td>n=6</td>
</tr>
</tbody>
</table>

* Chromogenic assay results significantly higher than clotting (p<0.01)
No significant differences between results obtained using different standards
Appendix 1: List of Participants.

Dr Jean Amiral, HYPHEN BioMed, Neuville-sur-Oise, France

Dr Eugenia Biguzzi & Ms Daniela Asti, A. Biauch Bonomi Hemophilia and Thrombosis Center, University of Milan and Department of Medicine and Medical Specialties, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy

Dr Peter Baker, John Radcliffe Hospital, Oxford, UK

Dr Paul Braun, bioMérieux Inc, Durham, USA

Dr S Berrier & Ms C Bisson, Diagnostica Stago, Quality Control, Franconville Cedex, France

Dr Peter Gärtner, Baxter Bioscience, Vienna, Austria

Ms Marilyn Johnston & Mrs Joanne McGrath, Hemostasis Reference Laboratory, Hamilton, Canada

Dr Barbara Kerbl, Technoclone GmbH, Vienna, Austria

Dr Steven Kitchen & Mr Peter Cooper, Royal Hallamshire Hospital, Sheffield, UK

Dr Chong Loh & Mr Matt Harvey, Therapeutic Goods Administration, Symonston, Australia

Dr Catherine Michalski, LFB, Lille, France

Sandy Morrison, Precision BioLogic Inc, Dartmouth, Canada

Dr Ingrid Pabinger-Fasching, University Hospital, Vienna, Austria

Dr William Pickering, NIBSC, South Mimms, UK

Dr Miriam Ramondetta & Mr Luigi Leo, DMCPO-University of Milan, Hematology and Thrombosis Unit and Transfusion Center, S. Paolo Hospital, Milan, Italy

Mrs Jeannette Rentenaar, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands

Dr Cheng-Hock Toh & Mr Alan Smith, Royal Liverpool University Hospital, Liverpool, UK

Dr Kathleen Trumbull & Dr Barbara Phillips, Instrumentation Laboratory, Lexington, USA

Dr Barry Woodhams, Diagnostica Stago, Research and Development, Gennevilliers, France

Dr Renata Zadro, Clinical Hospital Center Zagreb University School of Medicine, Zagreb, Croatia
Appendix 2: Proposed Instruction for Use and Material Safety Data

The 1st International Standard for Protein C, Concentrate, Human
04/252 (established 2007)
Instructions for Use (Version 1 July 2007)

1. INTRODUCTION

The 1st International Standard for Protein C, Concentrate, Human, consists of ampoules, coded 04/252, containing aliquots of a freeze-dried concentrate prepared from human plasma. This preparation was established as the 1st International Standard for Protein C, Concentrate, Human, by the Expert Committee on Biological Standardisation of the World Health Organisation in 2007.

The ECBS report is available from the WHO (www.who.int/biologicals). Document number: WHO/BS/07........

2. UNITAGE

The standard was value assigned in an international collaborative study involving 20 laboratories from 10 countries against the 2nd International Standard for Protein C, Plasma, Human, 02/342. The following potency was assigned based on the geometric mean of all the valid assay results:

- Functional (chromogenic assay only) : 15.0 IU/ampoule
- Antigenic: 14.5 IU/ampoule

NOTE: This standard has not been assigned with a functional activity by clotting assays and therefore should not be used for calibration of protein C activity by clot based methods.

Uncertainty: the assigned unitage does not carry an uncertainty associated with its calibration. The uncertainty may therefore be considered to be the variance of the ampoule content and was determined to be +/- 0.32 %.

3. CONTENTS

One vial (50,000 U/vial, ~100 ml) of plasma derived human protein C concentrate was thawed at 37°C and was further diluted with approximately 3.5 litres of 0.05M Tris, 0.15M NaCl, pH 7.4 containing 2 mg/ml trehalose and 5 mg/ml human albumin. The solution was distributed at 4°C into 3500 ampoules, coded 04/252. The mean weight of liquid content of 44 check weight ampoules was 1.0081g, with limits of 1.0037 - 1.0273g (coefficient of variation 0.32%). The contents of the ampoules were then freeze-dried under the conditions normally used for international biological standards1.

4. CAUTION
WHO/BS/07.2067
Page 11

**THIS PREPARATION IS NOT FOR ADMINISTRATION TO HUMANS.**

The preparation contains material of human origin, which has been tested and found negative for HBsAg, HIV antibody, HCV antibody and HCV RNA by PCR.

As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures probably will include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

5. **DIRECTIONS FOR OPENING THE DIN AMPOOLE**

DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider ampoule body.

Tap the ampoule gently to collect the material at the bottom (labelled) end. Ensure that the disposable ampoule safety breaker provided is pushed down on the stem of the ampoule and against the shoulder of the ampoule body. Hold the body of the ampoule in one hand and the disposable ampoule breaker covering the ampoule stem between the thumb and first finger of the other hand. Apply a bending force to open the ampoule at the coloured stress point, primarily using the hand holding the plastic collar.

Care should be taken to avoid cuts and projectile glass fragments that might enter the eyes, for example, by the use of suitable gloves and an eye shield. Take care that no material is lost from the ampoule and no glass falls into the ampoule. Within the ampoule is dry nitrogen gas at slightly less than atmospheric pressure. A new disposable ampoule breaker is provided with each DIN ampoule.

6. **USE OF AMPOULED MATERIAL**

Unopened ampoules should be stored in the dark at or below –20°C.

Allow ampoules to warm to room temperature. Open ampoule, taking care to ensure that all material is in the lower part, and reconstitute with 1.0 ml distilled water. Stand for 10 minutes at room temperature to allow complete dissolution of the material before use. The reconstituted Standard should be used as soon as possible.

7. **STABILITY**

It is the policy of WHO not to assign an expiry date to their international reference materials. They remain valid with the assigned potency and status until withdrawn or amended.

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities and should be stored on receipt as indicated on the label. Once reconstituted,
diluted or aliquoted, users should determine the stability of the material according to their own method of preparation, storage and use.

NIBSC follows the policy of WHO with respect to its reference materials. A preliminary accelerated degradation study, involving the potency estimation of ampoules stored at elevated temperatures (4, 20, 37, 45 °C) relative to ampoules stored at -150 °C was carried out in one laboratory (NIBSC), using the heparin co-factor chromogenic thrombin based assay. The observed relative loss of potency was analysed using the Arrhenius equation in order to provide a prediction of loss per year for ampoules stored at various temperatures. Estimates of % predicted loss of activity per year based on activities assessed at 3 different time points over a period of 9 months storage showed that there was no predicted loss of activity for samples stored at -20 °C, the storage temperature of the proposed IS, thus indicating that the preparation is exceedingly stable and suitable for long term use as an International Standard. The accelerated degradation study and real time monitoring will continue for the lifetime of the standard.

Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

Stability of the Proposed WHO 1st IS for Protein C, concentrate has been assessed in an accelerated degradation study which involves the potency estimation of ampoules stored at elevated temperatures relative to ampoules stored at -150 °C. The study was carried out in one laboratory (NIBSC), using a chromogenic assay with Protac® activation. To date, 16 months storage data is available. The observed relative potencies (from 2 independent assays) was analysed using the Arrhenius equation in order to provide a prediction of loss per year for ampoules stored at various temperatures. Because of insufficient loss of activities at the various temperatures and time points, the Arrhenius equation was unable to give a prediction of loss of activity per year. The accelerated degradation study and real time monitoring will continue for the lifetime of the standard.

8. CITATION

In any circumstance where the recipient publishes a reference to NIBSC materials, it is important that the title of the preparation and any NIBSC code number, and the name and address of NIBSC are cited correctly.

9. LIABILITY AND LOSS

Information provided by the Institute is given after the exercise of all reasonable care and skill in its compilation, preparation and issue, but it is provided without liability to the Recipient in its application and use.

It is the responsibility of the Recipient to determine the appropriateness of the materials supplied by the Institute to the Recipient (“the Goods”) for the proposed application and ensure that it has the necessary technical skills to determine that they are appropriate. Results obtained from the Goods are likely to be dependant on conditions of use by the Recipient and the variability of materials beyond the control of the Institute.
All warranties are excluded to the fullest extent permitted by law, including without limitation that the Goods are free from infectious agents or that the supply of Goods will not infringe any rights of any third party.

The Institute shall not be liable to the Recipient for any economic loss whether direct or indirect, which arise in connection with this agreement.

The total liability of the Institute in connection with this agreement, whether for negligence or breach of agreement or otherwise, shall in no event exceed 120% of any price paid or payable by the Recipient for the supply of the Goods.

If any of the Goods supplied by the Institute should prove not to meet their specification when stored and used correctly (and provided that the Recipient has returned the Goods to the Institute together with written notification of such alleged defect within seven days of the time when the Recipient discovers or ought to have discovered the defect), the Institute shall either replace the Goods or, at its sole option, refund the handling charge provided that performance of either one of the above options shall constitute an entire discharge of the Institute’s liability under this Condition.

10. References


For further information, please contact:

Dr Elaine Gray
Haemostasis Section
Biotherapeutics Group
NIBSC
Blanche Lane
South Mimms
Potters Bar
Hertfordshire EN6 3QG
UK

Tel: 00 44 1707 641319
Fax: 00 44 1707 641050
Email: egray@nibsc.ac.uk
11. MATERIAL SAFETY SHEET
The 1st International Standard for Protein C, Concentrate, Human 04/252
Version 1, 17 July 2007

<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is the material infectious or toxic (delete as necessary)?</td>
<td>NO</td>
</tr>
<tr>
<td>If yes, which containment level?</td>
<td></td>
</tr>
<tr>
<td>If no,</td>
<td></td>
</tr>
<tr>
<td>Does the formulation contain material of human origin?</td>
<td>YES</td>
</tr>
<tr>
<td>Does the formulation contain material of animal origin?</td>
<td>NO</td>
</tr>
<tr>
<td>Does the formulation contain azide?</td>
<td>NO</td>
</tr>
</tbody>
</table>

**Chemical properties:**

- Stable: ✔
- Corrosive: ✔
- Hygroscopic: ✔
- Oxidising: ✔
- Flammable: ✔
- Irritant: ✔
- Other (specify) contains material of human origin
- Handling: see safety compendium for handling material of human origin

**Toxicological properties:**

- Effects of inhalation: No adverse effects have been reported for this material
- Effects of ingestion: No adverse effects have been reported for this material
- Effects of skin absorption: No adverse effects have been reported for this material

**Suggested First Aid:**

- Inhalation: Seek medical advice
- Ingestion: Seek medical advice
- Contact with eyes: Wash with copious amounts of water. Seek medical advice
- Contact with skin: Wash with copious amounts of water. Seek medical advice

**Action on Spillage and Method of Disposal:**

- Spillage of material should be taken up with absorbent material wetted with a virucidal agent. Rinse area with a virucidal agent followed by water.
- Absorbent materials used to treat spillage should be treated as biologically hazardous waste.

Complied by E Gray, Haemostasis Section, Biotherapeutics

Signature: __________________________ Date: ____________